ASCO GU 2018: Transcriptomic Heterogeneity of Androgen Receptor Activity in Primary Prostate Cancer: Identification and Characterization of a Low AR-active Subclass

San Francisco, CA ( Dr. Spratt presented original work from a cross-institutional collaborative effort studying androgen receptor signaling and activity. The androgen receptor (AR) is a key player in the pathogenesis of prostate cancer (PC). We now know that dysregulation and/or mutation of the AR gene correlates with significant differences in PC-related outcomes. AR signaling is involved in many important pathways (DNA signaling, immune modulation, etc…). AR amplifications/mutations are common (and often actionable), and it is also known that AR-activity (ARA) may play an important role in PC pathogenicity. Genomic analyses show that ARA is highly variable in patients with localized PC. 

ASCO GU 2018: Medical Resource Utilization of Abiraterone Acetate Plus Prednisone added to ADT in Metastatic Castration-naive Prostate Cancer: Results from LATITUDE

San Francisco, CA ( The LATITUDE trial demonstrated that Abiraterone acetate and prednisone (AAP) + androgen deprivation therapy (ADT) exhibited significant improvements in overall survival (OS) and disease progression. The authors of this study aimed to assess event-driven medical resource utilization (MRU) from AAP + ADT vs ADT alone. 

ASCO GU 2018: Management of Oligometastatic Prostate Cancer From Imaging to Therapy

San Francisco, CA ( Felix Feng, MD presented on the topic of the management of oligometastatic prostate cancer. Oligometastatic disease is an intermediate state of cancer spread between localized disease and widespread metastases. The advent and increased utilization of PET imaging has caused the space of oligometastatic disease to increase (Figure 1). PET imaging has been increasingly used to detect extra-pelvic disease in patients with PSA recurrences. Specifically, the increased usage of PSMA PET imaging has been demonstrated to increase diagnosis of oligometastatic disease.

ASCO GU 2018: Impact of Decipher test on adjuvant and salvage treatments received following radical prostatectomy

San Francisco, CA ( Dr. John Gore form the University of Washington and colleagues presented their findings assessing the impact of the Decipher test on adjuvant and salvage radiation therapy among men undergoing radical prostatectomy. Indeed patients, their families, and providers have tremendous uncertainty as they decide on intervention with adjuvant or salvage radiation therapy after radical prostatectomy. As such, the objective of this study was to prospectively evaluate the impact of the Decipher test, a genomic classifier which predicts metastasis post-radical prostatectomy [1], on providers’ decision-making for adjuvant and salvage radiation therapy.

ASCO GU 2018: TPS383 - ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-sensitive Prostate Cancer

San Francisco, CA ( The addition of either docetaxel or abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improves overall survival (OS) compared with ADT alone in men with metastatic hormone sensitive prostate cancer (mHSPC). It is hypothesized that other androgen receptor (AR)-targeted therapies could be combined with docetaxel for mHSPC.

ASCO GU 2018: Shared decision making for prostate cancer screening: Reality or farce?

San Francisco, CA ( Dr. Daniel Pucheril and colleagues presented their assessment of shared decision making for prostate cancer screening. One of the core tenants of major cancer society guidelines with regards to prostate cancer screening is that providers must discuss both the advantages and disadvantages of screening with eligible patients in a shared decision making process. Shared decision making for prostate cancer screening includes a bi-directional sharing of information followed by consensus regarding the patient’s healthcare preferences. The objective of this study was to determine contemporary trends of shared decision making with regards to prostate cancer screening.

ASCO GU 2018: The FALCON Trial: Impact of 18F-fluciclovine PET/CT on Clinical Management Choices for Men with Biochemically Recurrent Prostate Cancer

San Francisco, CA ( Detection of the extent of local recurrence and of metastases in biochemical recurrence (BCR) of prostate cancer (PC) facilitates selection of appropriate treatment. The FALCON trial assessed the impact of 18F-fluciclovine PET/CT on the clinical management of men with PC BCR following initial radical therapy.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.